Alastair D. Reith
GlaxoSmithKline (United Kingdom)(GB)Age UK(GB)Accenture (United Kingdom)(GB)
Publications by Year
Research Areas
Parkinson's Disease Mechanisms and Treatments, Protein Kinase Regulation and GTPase Signaling, Cellular transport and secretion, Cancer-related gene regulation, Wnt/β-catenin signaling in development and cancer
Most-Cited Works
- → The Parkinson Progression Marker Initiative (PPMI)(2011)1,829 cited
- → SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7(2002)1,647 cited
- → Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases(2016)1,052 cited
- → Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription(2000)888 cited
- → Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization(2010)384 cited
- → Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death(2001)365 cited